{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:19:48Z","timestamp":1768457988697,"version":"3.49.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>In recent years, liver experts have conducted in-depth discussions on whether it is necessary to expand the indication of antiviral therapy for patients with chronic hepatitis B (CHB). Currently, the guidelines are too strict in treating CHB patients. With the deepening understanding of the natural history of hepatitis B virus infection, there is more and more evidence challenging the view that there is no disease progression and no treatment in the immune tolerance period and inactive period. As the price of antiviral agents for CHB has decreased significantly, the availability of antiviral agents for CHB has been considerably improved. Therefore, expanding the indications for antiviral treatment of CHB is of great significance in achieving the goal of eliminating the public health threat of viral hepatitis by 2030, as the World Health Organization has proposed.<\/jats:p>","DOI":"10.3389\/fmed.2023.1165891","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:58:32Z","timestamp":1684472312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The urgency to expand the antiviral indications of general chronic hepatitis B patients"],"prefix":"10.3389","volume":"10","author":[{"given":"Ping","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En-Qiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease","volume":"97","author":"Liu","year":"2019","journal-title":"China Bull World Health Organ"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.16505\/j.2095-0136.2016.02.001","article-title":"Hepatitis B control in China: progress, challenges and strategies","volume":"6","author":"Cui","year":"2016","journal-title":"Chinese J Viral Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.22476","article-title":"Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States","volume":"48","author":"Tong","year":"2008","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/jvh.13185","article-title":"The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria","volume":"26","author":"Sinn","year":"2019","journal-title":"J Viral Hepat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11684-017-0598-4","article-title":"Current advances in the elimination of hepatitis B in China by 2030","volume":"11","author":"Zhang","year":"2017","journal-title":"Front Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","article-title":"Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop","volume":"26","author":"Yim","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3760\/cma.j.cn501113-20220209-00060","article-title":"Expert opinion on expanding anti-HBV treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi.","volume":"30","author":"Wang","year":"2022"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jvh.13511","article-title":"Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone","volume":"28","author":"Yao","year":"2021","journal-title":"J Viral Hepat"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"103389","DOI":"10.1016\/j.ebiom.2021.103389","article-title":"A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection","volume":"67","author":"Chang","year":"2021","journal-title":"EBioMedicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.3748\/wjg.v27.i43.7497","article-title":"Hepatitis B: who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases","volume":"27","author":"Kawanaka","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","article-title":"Current treatment guidelines of chronic hepatitis B: the role of nucleos (t) ide analogues and peginterferon","volume":"31","author":"Ghany","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1109980","DOI":"10.3389\/fonc.2023.1109980","article-title":"The 20 years transition of clinical characteristics and metabolic risk factors in primary liver cancer patients from China","volume":"13","author":"Ding","year":"2023","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/liv.13705","article-title":"Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B: a large national cohort study","volume":"38","author":"Shim","year":"2018","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3748\/wjg.v23.i31.5746","article-title":"Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase","volume":"23","author":"Tan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hep4.1859","article-title":"Presence of liver inflammation in Asian patients with chronic hepatitis B with Normal ALT and detectable HBV DNA in absence of liver fibrosis","volume":"6","author":"Liu","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/apt.16067","article-title":"Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis","volume":"52","author":"Sonneveld","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0134532","DOI":"10.1371\/journal.pone.0134532","article-title":"A mechanistic assessment of the discordance between Normal serum alanine aminotransferase levels and altered liver histology in chronic hepatitis B","volume":"10","author":"Gong","year":"2015","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/jmv.25364","article-title":"Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase","volume":"91","author":"Liao","year":"2019","journal-title":"J Med Virol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for alanine aminotransferase levels: a 2021 update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.34172\/mejdd.2020.182","article-title":"Upper Normal limits of serum alanine aminotransferase in healthy population: a systematic review","volume":"12","author":"Kolahdoozan","year":"2020","journal-title":"Middle East J Dig Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100738","DOI":"10.1016\/j.lanwpc.2023.100738","article-title":"Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.12.001","article-title":"HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy","volume":"91","author":"Han","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jmv.25271","article-title":"Application strategies of serum HBV DNA detection in HBV infection patients: a retrospective study of 5611 specimens","volume":"91","author":"Liu","year":"2019","journal-title":"J Med Virol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/cncr.10557","article-title":"Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma","volume":"94","author":"Ohkubo","year":"2002","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.14218\/JCTH.2021.00046","article-title":"Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease","volume":"9","author":"Zhang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1186\/s12885-021-08483-3","article-title":"Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1111\/jgh.14750","article-title":"Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia","volume":"34","author":"Kim","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3350\/cmh.2020.0012","article-title":"Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/hep.27889","article-title":"Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load","volume":"62","author":"Sinn","year":"2015","journal-title":"Hepatology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3350\/cmh.2017.0005","article-title":"Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: real-life experience","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-virology-091919-062728","article-title":"Prospects for the global elimination of hepatitis B","volume":"8","author":"Block","year":"2021","journal-title":"Annu Rev Virol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/jmv.22048","article-title":"High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in Central Europe","volume":"83","author":"Gobel","year":"2011","journal-title":"J Med Virol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/ajg.2009.248","article-title":"Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels","volume":"104","author":"Nguyen","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e78672","DOI":"10.1371\/journal.pone.0078672","article-title":"Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent Normal ALT","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1038\/s41598-021-84556-4","article-title":"High-dimensional hepatopath data analysis by machine learning for predicting HBV-related fibrosis","volume":"11","author":"Pu","year":"2021","journal-title":"Sci Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jfma.2018.11.008","article-title":"Taiwan consensus statement on the management of chronic hepatitis B","volume":"118","author":"Chien","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23744235.2019.1675903","article-title":"Management of hepatitis B virus infection, updated Swedish guidelines","volume":"52","author":"Westin","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.cgh.2015.07.007","article-title":"A treatment algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 update","volume":"13","author":"Martin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jceh.2017.12.001","article-title":"INASL position statements on prevention, diagnosis and Management of Hepatitis B Virus Infection in India: the Andaman statements","volume":"8","author":"Arora","year":"2018","journal-title":"J Clin Exp Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"104783","DOI":"10.1016\/j.antiviral.2020.104783","article-title":"Reasons to consider early treatment in chronic hepatitis B patients","volume":"177","author":"Koffas","year":"2020","journal-title":"Antivir Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.cgh.2018.10.007","article-title":"Management algorithm for interrupting mother-to-child transmission of hepatitis B virus","volume":"17","author":"Hou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"pbac030","DOI":"10.1093\/pcmedi\/pbac030","article-title":"Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA. Precis","volume":"5","author":"Zhou","year":"2022","journal-title":"Clin Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1165891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:58:39Z","timestamp":1684472319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1165891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":53,"alternative-id":["10.3389\/fmed.2023.1165891"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1165891","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1165891"}}